JACC Asia - Efficacy and Safety of Sacubitril/Allisartan for the Treatment of Primary Hypertension

In this episode of the JACC: Asia podcast, Dr. Magnus O. Wijkman reviews a pivotal study comparing the angiotensin receptor neprilysin inhibitor sacubitril alisarmin with olmesartan for treating primary hypertension in Chinese patients. The trial found sacubitril alisarmin to be more effective in reducing blood pressure and well-tolerated, suggesting its potential as a new option for hypertension treatment, though further long-term studies are needed.